Menu
Back to Journals » OncoTargets and Therapy » Volume 5
The role of EGFR-targeting strategies in the treatment of head and neck cancer
Authors Dequanter D, Shahla M, paulus P, Lothaire P
Received 16 March 2012
Accepted for publication 20 June 2012
Published 27 July 2012 Volume 2012:5 Pages 127—131
DOI https://doi.org/10.2147/OTT.S31863
Review by Single anonymous peer review
Peer reviewer comments 4
Didier Dequanter, Mohammad Shahla, Pascal Paulus, Philippe H Lothaire
Department of Surgery, CHU Charleroi (Hopital Andre Vésale), Montigny le Tilleul, Belgium
Abstract: With its targeted mechanism of action and synergistic activity with current treatment modalities, cetuximab is a potentially valuable treatment option for patients with recurrent and/or metastatic squamous cell cancer of the head and neck who have progressed on cisplatin-based chemotherapy. The use of cetuximab in combination with radiotherapy as definitive treatment for locoregionally advanced squamous cell cancer of the head and neck is generally restricted to patients unfit to receive cisplatin-based chemoradiation, which is still considered the standard of care. The effect of this epidermal growth factor receptor antagonist occurs without any change in the pattern and the severity of toxicity usually associated with head and neck radiation.
Keywords: cetuximab, SCCHN, radiotherapy
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.